NCT00002235View on ClinicalTrials.gov

A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Indinavir sulfate

DRUG

Nelfinavir mesylate

DRUG

Efavirenz

Trial Locations (5)

23666

Hampton Roads Med Specialists, Hampton

30308

AIDS Research Consortium of Atlanta, Atlanta

80262

Univ of Colorado / Health Science Ctr, Denver

90211

Pacific Oaks Med Group, Beverly Hills

02908

Brown Univ School of Medicine, Providence

Sponsors

Collaborators (1)

Agouron Pharmaceuticals
All Listed Sponsors
collaborator

Agouron Pharmaceuticals

INDUSTRY

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00002235 - A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors | Biotech Hunter | Biotech Hunter